Auto Draft

Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

November 04, 2021 08:00 ET | Source: Neurona Therapeutics SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today...
Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease

Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease

September 27, 2021 – Alofisel (darvadstrocel) is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan – Alofisel provides a potential cell-mediated closure option for patients with complex perianal...